This article reports the results of the clinical trial which investigated the relationship between aspirin use and clinical outcomes in patients with known coronary artery disease (CAD). The patients received aspirin at baseline concomitant with either rivaroxaban or warfarin. Generally, the ischemic stroke due to arterial fibrillation (AF) has high mortality, and recurs frequently and has poor functional deficits than non-AF associated ischemic stroke.
In this regard, anticoagulation alleviates frequency and severity of the AF-associated ischemic stroke, thereby reducing mortality. In recent years, novel anticoagulants have been compared with vitamin K antagonists, but the relationship between the aspirin use and clinical outcomes in patients with AF is not very well known. The clinical trial was designed to understand this relationship while comparing rivaroxaban or warfarin therapy…
